Jump to page content Accessibility
News, views and contacts from the global Drugdevelopment industry
Login to drugdevelopment-technology.com Log in or Register
  • Home
  • Products & Services
  • Company A - Z
  • Projects
  • Features
  • Videos
  • White Papers
  • News
  • Events
  • Advertise With Us
Industry Projects | Projects by Region | Projects by Category | Archived Projects | Project Gallery
 

Dasatinib - Tyrosine Kinase Inhibitor for Chronic



Rates of response and survival

Rates of response and survival at 5 years in trials of chemotherapy, interferon and imatinib for CML

  • Formation of blood cells
    Some pathways and colony forming units (CFU) involved in the formation of...
  • Forms of blood cancer
    Relationship between stage of maturation of white blood cells and common...
  • Chromosome translocation
    The t(9:22) chromosome translocation in CML
  • Onset of CML
    Onset of CML, showing that peak occurrence is in people aged 50-70 years....
  • Rates of response and survival
    Rates of response and survival at 5 years in trials of chemotherapy,...

Back to Project Details



Related Projects

Naproxcinod (HCT 3012) - COX-Inhibiting Nitric Oxide-Donator
Developed by French pharmaceutical company NicOx, naproxcinod (HCT 3012)...

Capravirine - Anti-Retroviral Drug
Developed by Pfizer Global Research and Development, capravirine is...

Lyrica (Pregabalin) - New Gabapentinoid with Wide
Developed by Pfizer, pregabalin, marketed under the brand name Lyrica, is...

Xolair - Biological Therapy
The product of a joint development programme between Tanox, Genentech...

Acomplia (Rimonabant) - Investigational Agent for
Developed by Sanofi-Aventis, Acomplia (rimonabant) is a selective...

See all projects


Contact us
Advertise with us
Terms and conditions
Privacy
Links
Newsletter sign up
Online magazine sign up

drugdevelopment-technology.com is a product of Net Resources International. Copyright 2011 Net Resources International, a trading division of SPG Media Limited.